title: Montelukast versus inhaled corticosteroids in the management of pediatric mild persistent asthma.
abstract: International guidelines recommend the use of inhaled corticosteroids (ICSs) as the preferred therapy, with leukotriene receptor antagonists (LTRAs) as an alternative, for the management of persistent asthma in children. Montelukast (MLK) is the first LTRA approved by the Food and Drug Administration for the use in young asthmatic children.Therefore, we performed an analysis of studies that compared the efficacy of MLK versus ICSs. We considered eligible for the inclusion randomized, controlled trials on pediatric populations with Jadad score > 3, with at least 4 weeks of treatment with MLK compared with ICS.Although it is important to recognize that ICSs use is currently the recommended first-line treatment for asthmatic children, MLK can have consistent benefits in controlling asthmatic symptoms and may be an alternative in children unable to use ICSs or suffering from poor growth. On the contrary, low pulmonary function and/or high allergic inflammatory markers require the corticosteroid use.
authors.affiliation: Allergy and Respiratory Unit, Department of Pediatrics, G, D'Annunzio University of Chieti, Via Dei Vestini 5, Chieti, 66013, Italy. ale.scaparrotta@libero.it.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Scaparrotta
authors.forename: Sabrina
authors.initials: S
authors.lastname: Di Pillo
authors.forename: Marina
authors.initials: M
authors.lastname: Attanasi
authors.forename: Daniele
authors.initials: D
authors.lastname: Rapino
authors.forename: Anna
authors.initials: A
authors.lastname: Cingolani
authors.forename: Nicola Pietro
authors.initials: NP
authors.lastname: Consilvio
authors.forename: Marcello
authors.initials: M
authors.lastname: Verini
authors.forename: Francesco
authors.initials: F
authors.lastname: Chiarelli